Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 7/20 | 0.54 |
| ▸ | SOD1 | P00441 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439831 | 0.87 | MAOB (0.52) | NR4A1NR4A2NR4A3MAOBSOD1 | |
| SCHEMBL23540967 | 0.87 | MAOB (0.59) | SMPD1NR4A2MAOBRAB9AAPP | |
| SCHEMBL9503358 | 0.87 | MAOB (0.54) | SMPD1NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL13439789 | 0.83 | APP (0.66) | NR4A1NR4A2NR4A3MAOBRAB9A | |
| SCHEMBL4699319 | 0.82 | SMPD1 (0.64) | SMPD1MAOBRAB9AAPPSPHK2 | |
| SCHEMBL13761594 | 0.82 | NR4A2 (0.56) | NR4A1NR4A2NR4A3MAOBSOD1 | |
| SCHEMBL78171 | 0.82 | MAOB (0.62) | NR4A1NR4A2NR4A3MAOBSOD1 | |
| SCHEMBL13439834 | 0.81 | NPC1 (0.58) | SMPD1NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL11125159 | 0.81 | MAOB (0.57) | SMPD1NR4A1NR4A2NR4A3MAOB | |
| SCHEMBL13462937 | 0.79 | MAOB (0.61) | SMPD1MAOBSOD1RAB9ASPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | SMPD1 1026/4885NR4A1 1067/4885NR4A2 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.